Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Share News (OVB)

Share Price Information for Ovoca Bio (OVB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.85
Bid: 0.80
Ask: 0.90
Change: -0.05 (-5.56%)
Spread: 0.10 (12.50%)
Open: 0.90
High: 0.90
Low: 0.85
Prev. Close: 0.90
OVB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS UPDATES: Live Co revenue rises; Ovoca cautions on Russia

Thu, 30th Jun 2022 12:17

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Live Co Group PLC - Surrey, England-based live events, entertainment and sports events company - Revenue in 2021 climbs 44% to GBP2.7 million from GBP1.9 million. Pretax loss narrows to GBP3.3 million from GBP8.4 million. Hit from exceptional items much-reduced to GBP364,000 from GBP4.4 million. Live Co had registered transactional and reorganisational costs of GBP2.7 million in 2020. This fell to just GBP66,000 in 2021. Its key Bricklive unit was still hit by Covid in the first half of 2021, though majority of postponed events from 2020 took place last year. A handful are occurring in 2022.

----------

Ovoca Bio PLC - Dublin-based biopharmaceutical company focused on women's health - Pretax loss in 2021 widens to USD6.2 million from USD2.6 million in 2020. "Other administration expenses" surge to EUR7.1 million from EUR2.6 million. Ovoca does not report any revenue. Company notes it has operations in Russia, though this accounted for 10% of cashflow for 2021. Its Russian units are not subject to any sanctions and Ovoca says no member of its board or management are on list of sanctioned individuals. Ovoca does, however, say that punitive sanctions imposed on Russia, as well as the Kremlin's own counter measures, "may introduce some additional risks" to company. "In the event of realisation of some economic and political risks, it cannot be excluded that Ovoca operations in Russia can be limited, suspended or terminated," company adds. Says "continued focus" throughout 2021 was development of Orenetide, a treatment for hypoactive sexual desire disorder in pre-menopausal women.

----------

nanosynth group PLC - Nottingham, England-based digital monitoring and safeguarding systems manufacturer formerly known as Remote Monitored Systems - Pretax loss in 2021 stretches to GBP3.2 million from GBP968,905 in 2020. Revenue climbs to GBP208,778 in 2021 from a nominal figure of GBP600 in 2020. "During the year the Group refocused on the development and commercialisation of its core nano-particle platform technology and dispensed with non-core activities, including the return of Cloudveil Ltd to its founders and, the disposal of the majority of Gyrometric Systems Ltd," nanosynth says.

----------

Fox Marble Holdings PLC - London-based marble producer – Pretax loss in 2021 narrows to EUR1.9 million from EUR2.9 million. Revenue declines 9.8% to EUR646,064 from EUR715,900. Shares in company were suspended in April. Company at time arranges GBP400,000 funding by way of a convertible loan note to fund the acquisition of Eco Buildings Group Ltd. Fox Marble says in process of finalising its audited results for 2021. Will not be in position to present audited final results before the end of June 2022, therefore falling short of AIM obligations. "The delay in publication relates to the cumulative structural impact of Covid-19, including related staffing issues, on the accounts completion and audit process," Fox Marble says. "A further announcement will be made in due course on publication and posting of the company's audited final results."

---------

CleanTech Lithium PLC - Jersey-based lithium exploration and development company focused on Chile - The recent listing reports annual results for 2021, which was prior to its initial public offering. The year saw CleanTech conduct "successful work programme to prepare the company for listing on AIM". It raised GBP4.8 million across two pre-IPO funding rounds and appointed board and management team. Pretax loss in 2021 widens to GBP1.2 million from GBP144,334 in 2020. Administrative costs surge to GBP1.2 million from GBP139,223. CleanTech priced its March IPO at 30p per share. The stock was down 1.5% at 23.40p each in London on Thursday morning, down 22% from IPO price.

----------

Victoria Oil & Gas PLC - London-based oil and gas company - Says will not publish 2021 annual report ahead of Thursday's annual general meeting, due to uncertainty surrounding following legal ruling made in April. In April, company said its wholly-owned subsidiary Gaz du Cameroun SA was ordered by International Chamber of Commerce to pay USD12.1 million to RSM Production Corp. The legal proceedings had been ongoing since 2018 and concern their joint-venture. Says unaudited attributable revenue for 2021 was USD14.5 million, up 10% from USD13.2 million in 2020. Says for five months to May 31 in 2022, revenue amounts to USD6.3 million, up from USD6.2 million. According to the rules, of ICC arbitration, the legal verdict cannot be appealed and a payment must be made without delay. Victoria in April said neither itself nor its subsidiary have the means to make the payment without delay. This prompted the decision to suspend trading of Victoria Oil shares until the "fundamental uncertainty" resolves. Says unaudited cash and cash equivalents at end of 2021 was USD2.1 million, up from USD1.8 million in 2020.

----------

Kropz PLC - African phosphate developer - Pretax loss in 2021 balloons to USD18.3 million from USD2.0 million in 2020. Like 2020, Kropz does not post any annual revenue. "Activities during the year were focused on completion of construction activities at Elandsfontein and finalisation of the Hinda updated feasibility study," Kropz says. Elandsfontein is located in South Africa and Hinda at Republic of Congo.

----------

Ground Rents Income Fund PLC - invests in portfolio of long-dated ground rents from freeholds and head leases in the UK - In six months to March 31, net asset value per share shrinks 9.2% to 93.6 pence from 103.1p at September 30 year end. Dividends paid amount to 1.5p per share, down from 2.0p. Says "ground rent collection has remained in line with pre-pandemic collection rates levels". As of June 1, says 88.9% of total ground rent income for year to September 30 collected, versus 88.6% in financial 2021 and 82.8% in financial 2019, which was pre-pandemic.

----------

Secure Property Development & Investment PLC - south eastern Europe-focused commercial property investor - NAV per share at end of 2021 amounts to EUR0.18, unchanged from year prior. Says impact of Covid meant efforts to seal merger with Amsterdam and Prague-listed Arcona Property Fund NV taking more time than expected. "With the start of the year bringing improvements on the health front, the process picked up pace and is now progressing meeting SPDI's strategic objectives to create a regional property platform of reference in south eastern Europe by offering exposure to our shareholders to a much larger and broader east European regional property company," Secure Property says. Expects 2022 to be its final year of operations "as we know them". Its net assets are to be turned into shares in APF and cash "within the year or soon after".

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 Oct 2020 10:54

Russian Health Ministry Rejects Ovoca Bio's BP-101 Application

Russian Health Ministry Rejects Ovoca Bio's BP-101 Application

Read more
2 Oct 2020 10:10

Ovoca Bio hits stumbling block in Russia drug approval

(Sharecast News) - Biopharmaceutical company Ovoca Bio updated shareholders on Friday on its marketing authorisation application for BP-101, a novel synthetic peptide administered through a nasal spray, that was submitted to the Russian Ministry of Health (Minzdrav) in September 2019.

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
21 Sep 2020 21:19

IN BRIEF: Ovoca Bio Pretax Loss Widens In First Half Of 2020

IN BRIEF: Ovoca Bio Pretax Loss Widens In First Half Of 2020

Read more
26 Jun 2020 11:58

Ovoca Bio Annual Loss Slightly Narrows; Capital Base "Strong"

Ovoca Bio Annual Loss Slightly Narrows; Capital Base "Strong"

Read more
24 Mar 2020 18:39

Ovoca Bio Completes Buyout Of Russia's IVIX For USD5 Million

Ovoca Bio Completes Buyout Of Russia's IVIX For USD5 Million

Read more
16 Sep 2019 11:33

Ovoca Bio narrows losses as BP-101 trials continue

(Sharecast News) - Biopharmaceutical firm Ovoca Bio narrowed losses slightly in the first half of its trading year, while focus remained firmly on its continued development of a treatment for female sexual dysfunction.

Read more
16 Sep 2019 10:48

Ovoca Bio Interim Loss Widens On Administration Expenses

(Alliance News) - Ovoca Bio PLC on Monday said its loss widened in the first half of the year, suffering higher administration expenses in the year as it worked to develop its BP-101 female sexual

Read more
28 Aug 2019 14:43

Ovoca Bio Non-Executive Nikolay Myasoyedov Leaves For Personal Reasons

(Alliance News) - Ovoca Bio PLC on Wednesday said Non-Executive Director Nikolay Myasoyedov intends to step down from the board with immediate effect for personal reasons.The pharmaceutical

Read more
8 Aug 2019 11:24

Ovoca Bio's Libicore Application Result Expected A Year After Filing

(Alliance News) - Ovoca Bio PLC on Thursday said it intends to file for the approval of its Libicore female sexual dysfunction drug later in the quarter and expects the verdict in a year's 16%

Read more
26 Jul 2019 17:03

Ovoca Bio Says Non-Executive Director Yuri Radchenko Has Left Role

(Alliance News) - Drug company Ovoca Bio PLC said on Friday Yuri Radchenko, a non-executive director, has stepped down with immediate effect due to personal reasons.Chief Executive Kirill I

Read more
28 Jun 2019 15:07

Ovoca Bio Loss Widens; Prepares For Market Approval Filing For Libicore

(Alliance News) - Ovoca Bio PLC on Friday said its annual loss widened heavily as a result of administration expenses and said it is preparing to file for marketing approval of its drug BP101 in a

Read more
23 Apr 2019 15:40

Ovoca Bio's IVIX ropes in Biorasi for development of 'Libicore' drug candidate

(Sharecast News) - Ovoca Bio announced on Tuesday that its subsidiary IVIX has begun the process of preparing an integrated clinical development plan for its investigational drug candidate, 'Libicore' (BP-101), for both the US and EU regions with US-based contract research organisation Biorasi.

Read more
27 Mar 2019 10:21

Ovoca Bio Expands IVIX Stake Amid Strong Libicore Drug Trial Results

LONDON (Alliance News) - Ovoca Bio PLC said Wednesday it increased its stake in a majority-owned subsidiary following a positive set of test results from its Libicore sexual desire - known as Gold

Read more
25 Mar 2019 12:13

Ovoca Bio To Seek Russian Approval For Libicore After Successful Trial

LONDON (Alliance News) - Ovoca Bio PLC on Monday said it intends to file for the approval of its hypoactive sexual desire disorder drug Libicore in Russia after positive results from a recent in a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.